82 related articles for article (PubMed ID: 20414007)
1. Does guideline-adherent therapy improve the outcome for early-onset breast cancer patients?
Varga D; Wischnewsky M; Atassi Z; Wolters R; Geyer V; Strunz K; Kreienberg R; Woeckel A
Oncology; 2010; 78(3-4):189-95. PubMed ID: 20414007
[TBL] [Abstract][Full Text] [Related]
2. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
[TBL] [Abstract][Full Text] [Related]
3. Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients.
Schwentner L; Wolters R; Wischnewsky M; Kreienberg R; Wöckel A
Breast; 2012 Apr; 21(2):171-7. PubMed ID: 21945313
[TBL] [Abstract][Full Text] [Related]
4. Effects of guideline adherence in primary breast cancer--a 5-year multi-center cohort study of 3976 patients.
Wöckel A; Kurzeder C; Geyer V; Novasphenny I; Wolters R; Wischnewsky M; Kreienberg R; Varga D
Breast; 2010 Apr; 19(2):120-7. PubMed ID: 20117932
[TBL] [Abstract][Full Text] [Related]
5. [Effects of guideline-compliant therapy on the survival of primary breast cancer patients with: results of a retrospective cohort study].
Wolters R; Wöckel A; Wischnewsky M; Kreienberg R
Z Evid Fortbild Qual Gesundhwes; 2011; 105(6):468-75. PubMed ID: 21843852
[TBL] [Abstract][Full Text] [Related]
6. Participation in adjuvant clinical breast cancer trials: does study participation improve survival compared to guideline adherent adjuvant treatment? A retrospective multi-centre cohort study of 9,433 patients.
Schwentner L; Van Ewijk R; Kurzeder C; Hoffmann I; König J; Kreienberg R; Blettner M; Wöckel A
Eur J Cancer; 2013 Feb; 49(3):553-63. PubMed ID: 22959469
[TBL] [Abstract][Full Text] [Related]
7. Impact of guideline conformity on breast cancer therapy: results of a 13-year retrospective cohort study.
Wöckel A; Varga D; Atassi Z; Kurzeder C; Wolters R; Wischnewsky M; Wulff C; Kreienberg R
Onkologie; 2010; 33(1-2):21-8. PubMed ID: 20164658
[TBL] [Abstract][Full Text] [Related]
8. Adherence to quality indicators and survival in patients with breast cancer.
Cheng SH; Wang CJ; Lin JL; Horng CF; Lu MC; Asch SM; Hilborne LH; Liu MC; Chen CM; Huang AT
Med Care; 2009 Feb; 47(2):217-25. PubMed ID: 19169123
[TBL] [Abstract][Full Text] [Related]
9. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
[TBL] [Abstract][Full Text] [Related]
10. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
[TBL] [Abstract][Full Text] [Related]
11. Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients.
Wolters R; Wöckel A; Janni W; Novopashenny I; Ebner F; Kreienberg R; Wischnewsky M; Schwentner L;
Breast Cancer Res Treat; 2013 Dec; 142(3):579-90. PubMed ID: 24258258
[TBL] [Abstract][Full Text] [Related]
12. Comparison of early onset breast cancer patients to older premenopausal breast cancer patients.
Varga D; Koenig J; Kuhr K; Strunz K; Geyer V; Kurzeder C; Atassi Z; Blettner M; Kreienberg R; Woeckel A
Arch Gynecol Obstet; 2010 Oct; 282(4):427-32. PubMed ID: 20047053
[TBL] [Abstract][Full Text] [Related]
13. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
Fisher B; Jeong JH; Anderson S; Wolmark N
J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
[TBL] [Abstract][Full Text] [Related]
14. Is guideline adherence the key to increased survival in patients with breast cancer?
Hoffmann F; Andersohn F
Oncology; 2010; 79(3-4):301-2; author reply 303-5. PubMed ID: 21412015
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemotherapy in stage III breast cancer.
Alassas M; Chu Q; Burton G; Ampil F; Mizell J; Li BD
Am Surg; 2005 Jun; 71(6):487-92. PubMed ID: 16044927
[TBL] [Abstract][Full Text] [Related]
16. Improved survival for women with stage I breast cancer in south-east Sweden: a comparison between two time periods before and after increased use of adjuvant systemic therapy.
Johansson P; Fohlin H; Arnesson LG; Dufmats M; Nordenskjöld K; Nordenskjöld B; Stål O;
Acta Oncol; 2009; 48(4):504-13. PubMed ID: 19235568
[TBL] [Abstract][Full Text] [Related]
17. Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients.
Kennedy T; Stewart AK; Bilimoria KY; Patel-Parekh L; Sener SF; Winchester DP
Ann Surg Oncol; 2007 Oct; 14(10):2918-27. PubMed ID: 17638060
[TBL] [Abstract][Full Text] [Related]
18. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
Chapman JA; Lickley HL; Trudeau ME; Hanna WM; Kahn HJ; Murray D; Sawka CA; Mobbs BG; McCready DR; Pritchard KI
Breast J; 2006; 12(1):37-47. PubMed ID: 16409585
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.
Kim HS; Yom CK; Kim HJ; Lee JW; Sohn JH; Kim JH; Park YL; Ahn SH
Breast Cancer Res Treat; 2010 Jun; 121(3):777-88. PubMed ID: 19806450
[TBL] [Abstract][Full Text] [Related]
20. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
